CLAIMS

~~What is claimed is:~~

1. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,



(III)

wherein

R_1 is selected from H, C_{1-3} alkyl and C_{3-5} cycloalkyl, wherein the C_{1-3} alkyl and C_{3-5} cycloalkyl are optionally substituted by 1, 2 or 3 R_a;

R_2 and R_3 are each independently C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_b;

R_4 is selected from H, F, Cl, Br, I and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_c;

R_5 is selected from F, Cl, Br, I and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted by 1, 2 or 3 R_e;

m is selected from 0, 1 and 2;

n is selected from 0, 1 and 2;

ring A is selected from pyrazolyl and tetrahydropyranyl, wherein the pyrazolyl and tetrahydropyranyl are optionally substituted by 1, 2 or 3 R_d;

R_a, R_b, R_c and R_e are each independently selected from D, F, Cl, Br, I, OH and OCH_3;

R_d is selected from F, Cl, Br, I, CH_3 and OCH_3.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_1 is selected from H, CH_3, and cyclopropyl, wherein the CH_3 and cyclopropyl are optionally substituted by 1, 2, or 3 R_a.

3. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein R_1 is selected from H, CH_3, CHF_2, CD_3, $CH_2CH_2OCH_3$ and cyclopropyl.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_2 and R_3 are each independently selected from CH_3 and CH_2CH_3, wherein the CH_3 and CH_2CH_3 are optionally substituted by 1, 2 or 3 R_b.

5. The compound or pharmaceutically acceptable salt thereof according to claim 4, wherein R_2 and R_3 are each independently CH_3.

6. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_4 is selected from H, F, Cl, Br, I and CH_3, wherein the CH_3 is optionally substituted by 1, 2 or 3 R_c.

7. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein R_4 is selected from H, F, Cl, Br, I and CH_3.

8. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_5 is selected from F, Cl, Br, I and CH_3, wherein the CH_3 is optionally substituted by 1, 2 or 3 R_e.

9. The compound or pharmaceutically acceptable salt thereof according to claim 8, wherein R_5 is selected from F, Cl, Br, I and CH_3.

10. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from ,  and , wherein the ,  and  are optionally substituted by 1, 2, or 3 R_d.

11. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein

ring A is selected from , ,  and .

12. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety  is selected from ,  and .

13. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein the structural moiety  is selected from ,  and .

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-9, wherein the compound is selected from



（I-1）



（I-2）



（III-1）



（III-2），

wherein

R_1 is as defined in any one of claims 1-3;

R_2 and R_3 are as defined in any one of claims 1, 4 or 5;

R_4 is as defined in any one of claims 1, 6 or 7;

R_5 is as defined in any one of claims 1, 8 or 9;

m is as defined in claim 1.

15. A compound represented by the following formula or a pharmaceutically acceptable salt thereof,



.

16. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15 in the manufacture of a medicament for treating diseases related to ERK.

17. The use according to claim 16, characterized in that the medicament for treating diseases related to ERK ~~inhibitor~~ is a medicament for treating solid tumor.

18. A medicament, comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15.